Executive summary
United States Patent 9,624,260 is a process patent covering large-scale capture and separation of multiple human blood proteins from serum or plasma using a specific “no alcohol supplementation” workflow: pH adjustment (3 to 10), ionic strength/conductivity adjustment, adsorption onto a high-density non-porous-core/porous-shell particle adsorbent, collection of a non-bound fraction for downstream processing, and elution of bound proteins. The dependent claims expand coverage across specific protein targets (albumin, IgG, α1-proteinase inhibitor, fibrinogen, transferrin, complement, coagulation/anticoagulation factors) and include optional virus inactivation steps (with detergent/organic solvent additions such as polysorbate detergents and tri-n-butyl phosphate).
Critical licensing and freedom-to-operate angle: claim scope is anchored to an adsorption column process using a defined class of adsorbent particles (density ≥1.5 g/mL; mean volume particle diameter ≤150 µm; non-porous high-density core surrounded by porous material) plus the “protein solution not supplemented with alcohol” limitation. Competitors can reduce risk by changing at least one of these anchors: replace alcohol-free feed handling, avoid the specified adsorption particle architecture, or change the fractionation logic so that the “non-bound fraction further processed to obtain at least one non-bound protein” is not performed as claimed.
US Patent 9,624,260 claims analysis: what process steps must a facility practice to infringe?
Core independent claim structure (Claim 1)
Infringement requires all elements below in one process practice, in substance and sequence:
- Input protein source: protein solution obtained from human blood or blood-derived solution.
- Alcohol limitation: the protein solution is not supplemented with an alcohol.
- Preconditioning:
- pH adjusted to 3 to 10.
- Ionic strength and/or conductivity adjusted to:
- ionic strength 0.0001 to 12, or
- conductivity 0.01 to 1000 mS/cm.
- Adsorption step: apply the prepared protein solution to an adsorption column with an adsorbent that has:
- a high density non-porous core surrounded by porous material,
- particle density ≥ 1.5 g/mL,
- mean volume particle diameter ≤ 150 µm,
- proteins bind to the adsorbent.
- Fractionation: collect non-bound material fraction containing one or more non-bound proteins.
- Elution: elute bound proteins from the adsorbent using one or more elution buffers, yielding a bound material fraction.
- Downstream from non-bound: subject the non-bound fraction to further processing to obtain at least one non-bound protein.
Claim 1’s strongest “infringement locks”
- Adsorbent particle architecture + size/density. Many chromatography processes exist in protein separations. This claim narrows to a specific adsorbent particle morphology and measurable particle properties.
- Non-alcohol feed. If a facility uses ethanol or other alcohol supplementation in the feed conditioning stage, it may fall outside this limitation.
- Two-fraction workflow. The claim requires non-bound fraction handling plus elution of bound material. A design that routes everything through bound elution only, or that discards non-bound fractions without obtaining non-bound proteins, can reduce claim coverage.
Claim 1’s likely practical breadth
- The pH and ionic/conductivity ranges are broad enough to overlap with standard bioprocess conditioning windows.
- The elution buffer content is not limited by composition in Claim 1, only by functional elution of bound proteins. That supports broad infringement risk if the adsorbent and fractionation logic match.
What patents protect alcohol-free adsorption-column isolation of human serum/plasma proteins like albumin and α1-proteinase inhibitor?
This patent is written as a platform-style process claim. The likely competitive reality is that the field contains a layered patent landscape:
Adsorbent-family IP (architecture-centric)
Your strongest counterparty risk usually comes from adsorbent chemistry and particle design patents rather than from process parameter patents alone. Claim 1 forces the adsorbent into a specific class:
- High-density non-porous core
- porous surrounding material
- particle density ≥1.5 g/mL
- mean volume particle diameter ≤150 µm
If a competitor uses a different bead architecture (eg, porous core/porous particle without non-porous high-density core, or substantially different particle size distribution), it may avoid one or more required elements.
Process-step IP (workflow-centric)
Even if an adsorbent is similar, process patents can require:
- preconditioning ranges,
- two-fraction collection and separate handling,
- “no alcohol supplementation” feed treatment.
Claim 1’s “non-bound fraction further processed” element is a meaningful differentiator in practice.
Virus elimination step IP (treatment-centric)
Claims 3–5 add an optional but defined “virus elimination treatment” pathway:
- detergent/organic solvent additions,
- and (in Claim 4) being performed prior to contacting the protein solution with the adsorbent.
If a competitor omits virus treatment entirely (or performs it after adsorption), dependent claims 3–5 may not attach.
Which dependent claims expand coverage for specific proteins and multi-fraction separation?
Protein target lists and what they add
Claim 2 narrows to “human blood proteins from human blood solutions.”
Claim 7 lists a large set of human plasma/serum proteins; Claim 16 repeats a broad list but adds multi-fraction isolation.
Claim coverage matters because competitors may target fewer proteins. If the asserted claim is limited to specific protein identities in a dependent claim, their process must match those protein targets as bound and/or non-bound fractions.
Multi-fraction scope (Claims 16–18 and 49–56)
- Claim 16: at least 2 proteins isolated in at least 2 fractions.
- Claims 49–56: explicit “3 proteins in 3 fractions” up to “6 proteins in 6 fractions.”
This has two business implications:
- If a competitor’s process yields fewer product fractions than the dependent claim expects, those dependent claims are not a clean fit.
- In litigation, plaintiffs often still assert Claim 1 (broad framework) even if products are fewer, because Claim 1 does not require a specific number of protein species.
Specific binding/non-binding assignments (Claims 9, 19, 21–28, 31–37, 40–46)
These dependent claims can matter if a competitor’s separation behavior is different.
Examples:
- Claim 9: non-bound protein is α1-proteinase inhibitor.
- Claim 19: albumin and IgG bound, α1-proteinase inhibitor non-bound.
- Claims 21–24: fibrinogen and IgG bound while albumin can be non-bound; or fibrinogen/albumin/IgG bound with α1-proteinase inhibitor non-bound.
- Claim 27: fibrinogen/albumin/IgG bound; α1-acid glycoprotein and/or α1-proteinase inhibitor non-bound.
Coagulation/anticoagulation factor related coverage (Claims 18, 36–38, 45–47)
Claims 18 and 36–37 specify binding/non-binding involving clotting cascade proteins and inhibitors:
- Factor II, V, VII, VIII, IX, X, XI, von Willebrand factor,
- Factor VIII-vWF complex,
- C1 inhibitor, protein C, protein S.
These dependent claims create higher infringement specificity but also broaden target applicability for plasma fractionation platforms.
What adsorbent characteristics are required, and how do they affect design-around strategy?
Adsorbent definition in Claim 1 and Claim 29 (architecture class)
- “particle with at least one high density non-porous core, surrounded by a porous material”
- “particle density at least 1.5 g/ml”
- “mean volume particle diameter at most 150 µm”
Design-around levers
- Change particle size distribution: if median/mean volume particle diameter reliably exceeds 150 µm, the claim’s element can be avoided.
- Change density: if measured particle density is below 1.5 g/mL, risk decreases.
- Change morphology: removing the “non-porous core surrounded by porous material” architecture can avoid the defined adsorbent type.
- Change the role of the column: if a process uses different unit operations than adsorption-column contact as claimed (eg, non-column batch adsorption, or membrane adsorption not operating as an adsorption column), the fit may weaken.
A key point for a freedom-to-operate assessment: these are measurable properties. Competitors commonly have internal spec sheets and characterization data. If they can maintain consistent characterization outside the numeric ranges, claim mapping can become brittle for the patentee.
When does exclusivity end for US 9,624,260, and what does that mean for generic or competing process entry?
No filing data, priority dates, or legal status (expiration, terminal disclaimer, PTA, or reexamination history) were provided in the prompt. Without those facts, an accurate expiration timeline for US 9,624,260 cannot be produced.
How do virus elimination dependent claims change infringement risk?
Claims 3–5 (virus elimination)
- Claim 3: process further comprising at least one virus elimination treatment.
- Claim 4: virus elimination performed prior to contacting the protein solution with the adsorbent.
- Claim 5: virus elimination involves addition of detergent and/or organic solvent.
Claim 59 adds example agents
Detergent/solvent selection (examples):
- polysorbate detergents,
- octylphenol ethoxylate detergents,
- tri-n-butyl phosphate (TnBP).
Risk impact
- If a competitor performs virus inactivation after adsorption, then dependent claims 4 and potentially 3/5 in combination may not be asserted cleanly.
- If they use detergent/solvent types outside the examples, Claim 5 still covers “detergent and/or organic solvent” broadly, so omission is more effective than substitution unless the alternative method is outside the claim’s treatment categorization.
Orange Book status and FDA exclusivity: is this patent tied to an approved drug?
Process patents like this often support biologics or plasma-derived products, but Orange Book status depends on whether the patent is listed for a specific FDA approval and NDA/BLA. No FDA product linkage was provided, so Orange Book/BLA listing cannot be determined from the prompt alone.
What patent litigation risks exist for alternative adsorption chromatography and plasma protein purification workflows?
Without docket numbers, parties, or court outcomes, a litigation status map cannot be produced from the provided information.
How strong is the patent estate for this specific process class versus competing platform technologies?
Strength indicators inside the claim set
- Claim 1 is a comprehensive process recipe, with an adsorbent definition that narrows the universe of likely infringers.
- Broad preconditioning parameter ranges (pH 3–10, conductivity/ionic strength broad) reduce the chance that a competitor can avoid infringement by minor buffering changes.
- The “alcohol not supplemented” limitation provides a key factual and operational gate.
Vulnerability indicators for enforcement
- The adsorbent definition is specific but may be contested via particle characterization. If a competitor can show their adsorbent is materially different in density, particle size, or internal morphology, infringement can fail even if the general separation concept is similar.
- Dependent claims tied to specific protein identities and binding/non-binding assignments are narrower. If competitor products differ in which proteins end up bound vs non-bound, dependent claim attachment weakens.
- If competitor processes introduce an alcohol at any feed-conditioning stage, they can attempt a non-infringement stance against Claim 1 itself.
Claim chart style infringement mapping (high-information checklist)
A facility seeking to assess risk should verify each element:
A. Feed and conditioning
- Is feed derived from human blood/serum/plasma? (Yes/No)
- Is feed expressly not supplemented with an alcohol? (Yes/No)
- Is pH adjusted to 3–10 prior to column? (Yes/No)
- Is ionic strength 0.0001–12 or conductivity 0.01–1000 mS/cm adjusted? (Yes/No)
B. Column and adsorbent
- Is there an adsorption column contacting the conditioned feed? (Yes/No)
- Does the adsorbent particle have: non-porous high-density core + porous surround? (Yes/No)
- Is particle density ≥1.5 g/mL? (Yes/No)
- Is mean volume particle diameter ≤150 µm? (Yes/No)
C. Separation logic
- Does the process produce a non-bound fraction that contains at least one non-bound protein? (Yes/No)
- Is that non-bound fraction further processed to isolate non-bound proteins? (Yes/No)
- Are bound proteins eluted with one or more elution buffers? (Yes/No)
D. Optional features
- Is virus elimination included and performed prior to column contact? (Yes/No)
- Does virus treatment use detergent and/or organic solvent? (Yes/No)
This checklist corresponds directly to Claim 1 + dependent claim locks.
Key Takeaways
- US 9,624,260 is anchored to a defined adsorption-column process for human blood proteins with three hard gates: (i) alcohol-free feed, (ii) specific pH and ionic/conductivity conditioning windows, and (iii) a particle adsorbent architecture with measurable density and particle size.
- The broadest enforceable hook is Claim 1’s combination of adsorption onto that specific adsorbent class, separation into bound vs non-bound fractions, and further processing of non-bound fraction proteins.
- Design-around is most credible through measurable adsorbent property divergence (density, particle size, internal morphology), or by introducing alcohol supplementation into the feed conditioning step.
- Dependent claims add specificity for virus elimination timing and for particular protein targets and bound/non-bound behavior, which can narrow infringement scope when competitors target different product profiles.
FAQs
-
Can a process avoid infringement by changing only pH within the 3–10 band?
No. Claim 1 requires pH in the 3–10 range, so small deviations still within that band remain mapped.
-
Does using detergents for viral inactivation automatically add dependent-claim exposure?
Only if virus elimination is included, uses detergent and/or organic solvent, and (for Claim 4) is performed prior to contacting the adsorbent.
-
If a competitor elutes all proteins and discards the non-bound fraction, do dependent claims still apply?
Claim 1 requires further processing to obtain at least one non-bound protein from the non-bound fraction. Discarding non-bound material can reduce fit against Claim 1.
-
How important is the adsorbent particle diameter limit (≤150 µm)?
High. It is a hard numeric constraint tied to infringement mapping through the defined adsorbent element.
-
Do dependent claims require that albumin and IgG be bound and α1-proteinase inhibitor non-bound?
Only where those assignments are claimed in the asserted dependent claims (eg, Claim 19). Independent Claim 1 does not require the specific assignment of albumin/IgG vs α1-proteinase inhibitor.
References (APA)
- United States Patent 9,624,260. (Claims text provided in prompt).
